October 24th 2024
For patients with biochemical recurrence of prostate cancer, PSMA PET imaging may facilitate a 12.8 percent lower incidence of prostate cancer mortality in contrast to the combination of CT and bone scan, according to long-term outcome estimates from a new decision-analytic modeling study.
Study Shows MRI-Targeted Biopsies Reduce Overdiagnosis of Clinically Insignificant PCa by 57 Percent
September 27th 2024Omitting biopsy procedures in men with PSA levels > 3 ng/ml and negative MRI findings for prostate cancer (PCa) was associated with significantly lower risks of diagnosing clinically insignificant PCa in comparison to the use of systematic biopsy, according to an approximately four-year study of over 13,000 men who had prostate cancer screening.
PSMA PET/CT or mpMRI: Which is Better for Diagnosing Biochemical Recurrence of PCa?
September 24th 2024A new meta-analysis found that PSMA PET/CT offers a 12 percent higher positivity rate for detecting biochemical recurrence of PCa and a 19 percent higher positivity rate for identifying lymph node metastasis in comparison to mpMRI.
Emerging PSMA Radioligand Therapy Shows Benefits for Metastatic Castration-Resistant Prostate Cancer
September 16th 2024The PSMA-targeted modality 177Lu-PNT2002 improved radiographic progression-free survival by 29 percent in patients with mCRPC in comparison to ARPI therapy, according to new phase 3 trial data presented at the ESMO Congress in Spain.
Can Targeted PSMA PET/CT-Guided Radiotherapy Have an Impact for Oligometastatic Prostate Cancer?
August 6th 2024Emerging research revealed a median progression-free survival of 16.4 months and a 29-month mean freedom from a new line of systemic therapy for the use of PSMA PET/CT guided, metastasis-targeted radiotherapy for patients with oligometastatic castration-resistant PCa.
MRI-Based AI Radiomics Model Offers 'Robust' Prediction of Perineural Invasion in Prostate Cancer
July 26th 2024A model that combines MRI-based deep learning radiomics and clinical factors demonstrated an 84.8 percent ROC AUC and a 92.6 percent precision-recall AUC for predicting perineural invasion in prostate cancer cases.
Study: PSMA PET/CT More Advantageous than MRI for Locoregional Staging of Prostate Cancer
July 8th 2024For men with prostate cancer, new research demonstrates that 18F-PSMA-1007 PET/CT is 17 percent more accurate than mpMRI at identifying the final pathological tumor stage and 12 percent more accurate in detecting extracapsular extension.
Could MRI-Based AI Offer Better Risk Stratification for Prostate Cancer than PI-RADS?
July 3rd 2024The combination of deep learning assessment of prostate MRI with PI-RADS classification at a 15 percent risk threshold spared 49 percent of biopsies in comparison to 37 percent employing a PI-RADS>4 only cut-ff approach, according to new research.
What New Research Reveals About PSMA PET/CT and Oligorecurrent Prostate Cancer
June 27th 2024For patients with oligorecurrent prostate cancer, the use of PSMA PET/CT guidance for metastasis-directed therapy (MDT) provided over 19 months more median progression-free survival than choline PET/CT guidance, according to newly published research.
MRI-Based AI Model Facilitates 50 Percent Reduction in False Positives for Prostate Cancer
June 18th 2024In comparison to radiologists, new MRI research shows an emerging artificial intelligence (AI) model demonstrated a higher AUROC and a 14.8 percent higher positive predictive value for detecting prostate cancer at a mean PI-RADS 3 or greater operating point.
Study: Adjunctive AI Imaging Software Enhances Contouring of Prostate Cancer
June 13th 2024Artificial intelligence (AI) assisted contouring of prostate cancer demonstrated superior balanced accuracy than manual standard-of-care contouring and hemigland contouring with MRI, according to a new study.